NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 50% | – | – | – |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -2,341.4% | – | – | – |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -4,511.3% | – | – | – |
| EPS Diluted | -0.77 | 0.15 | -0.67 | -0.25 |
| % Growth | -613.3% | 122.4% | -168% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |